Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of sorafenib on soluble angiogenic factors in unresectable hepatocellular carcinoma
2007-005395-14Phase 2Active
- Sponsor
- RICARDO MORENO OTERO/MARIA CHAPARRO SANCHEZ
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by RICARDO MORENO OTERO/MARIA CHAPARRO SANCHEZ. Primary endpoint: Serum levels of angiogenic and related factors. Started Nov 2007; status: active.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2007-005395-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005395-14.